{"id":"furosemide-intravenous-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Hyperuricemia"},{"rate":null,"effect":"Ototoxicity (with high doses)"},{"rate":null,"effect":"Dehydration"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hyponatremia"}]},"_chembl":{"chemblId":"CHEMBL35","moleculeType":"Small molecule","molecularWeight":"330.75"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Furosemide is a loop diuretic that blocks the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, preventing reabsorption of sodium, potassium, and chloride. This increases urine output and reduces total body fluid volume, thereby decreasing preload on the heart and lowering blood pressure. The intravenous formulation provides rapid onset of action, making it useful in acute settings.","oneSentence":"Furosemide inhibits sodium and chloride reabsorption in the ascending loop of Henle, promoting diuresis and reducing fluid volume.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:30:53.322Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Edema associated with congestive heart failure"},{"name":"Edema associated with hepatic cirrhosis"},{"name":"Edema associated with renal disease"},{"name":"Hypertension"},{"name":"Acute pulmonary edema"}]},"trialDetails":[{"nctId":"NCT07263035","phase":"PHASE4","title":"Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure","status":"NOT_YET_RECRUITING","sponsor":"Lakeland Regional Health Systems, Inc.","startDate":"2026-01-01","conditions":"Heart Failure, Heart Failure - NYHA II - IV, Heart Failure Acute","enrollment":600},{"nctId":"NCT04201704","phase":"NA","title":"Effect of Giving Reduced Fluid in Children After Trauma","status":"RECRUITING","sponsor":"Columbia University","startDate":"2018-08-27","conditions":"Critical Illness, Pediatrics, General Surgery","enrollment":250},{"nctId":"NCT06886191","phase":"NA","title":"PuO2 in RenalGuard Pilot Study","status":"NOT_YET_RECRUITING","sponsor":"Sahlgrenska University Hospital","startDate":"2025-03-17","conditions":"Cardiac Surgery Subjects","enrollment":30},{"nctId":"NCT05962255","phase":"PHASE3","title":"Sodium Chloride vs. Glucose Solute as a Volume Replacement Therapy During Decongestion in Acute Heart Failure","status":"COMPLETED","sponsor":"Wroclaw Medical University","startDate":"2022-02-01","conditions":"Acute Heart Failure, Congestion, Heart Failure","enrollment":50},{"nctId":"NCT06442280","phase":"PHASE4","title":"SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF","status":"NOT_YET_RECRUITING","sponsor":"University of Palermo","startDate":"2024-06","conditions":"Heart Failure Acute, Diabetes Type 2, Heart Failure With Reduced Ejection Fraction","enrollment":544},{"nctId":"NCT05098366","phase":"EARLY_PHASE1","title":"Furosemide Use to Fill the Bladder of Pediatric Females Awaiting Pelvic Ultrasound","status":"COMPLETED","sponsor":"Connecticut Children's Medical Center","startDate":"2021-05-29","conditions":"Ovarian Torsion","enrollment":42},{"nctId":"NCT02055872","phase":"PHASE3","title":"Furosemide and Albumin for Diuresis of Edema: A Pilot Randomized Controlled Trial","status":"COMPLETED","sponsor":"Hamilton Health Sciences Corporation","startDate":"2014-09","conditions":"Edema, Hypoproteinemia","enrollment":46},{"nctId":"NCT04533997","phase":"PHASE3","title":"Hypertonic Saline Therapy in Ambulatory Heart Failure Unit.","status":"COMPLETED","sponsor":"Puerta de Hierro University Hospital","startDate":"2021-01-01","conditions":"Heart Failure","enrollment":167},{"nctId":"NCT01474200","phase":"NA","title":"Study of Heart Failure Hospitalizations After Aquapheresis Therapy Compared to Intravenous (IV) Diuretic Treatment","status":"TERMINATED","sponsor":"Nuwellis, Inc.","startDate":"2012-01","conditions":"Heart Failure, Cardiac Failure, Acute Decompensated Heart Failure (ADHF)","enrollment":224},{"nctId":"NCT05298098","phase":"NA","title":"Impact of Hypertonic Saline Solution on Acute Decompensated Heart Failure","status":"UNKNOWN","sponsor":"University of Monastir","startDate":"2018-07-01","conditions":"Acute Decompensated Heart Failure","enrollment":600},{"nctId":"NCT05807152","phase":"NA","title":"Furosemide-induced Diuresis With Matched Dehydration Compared to Standard Diuretic Therapy in Patients With Acute Heart Failure and Overt Fluid Overload","status":"UNKNOWN","sponsor":"Centro Cardiologico Monzino","startDate":"2019-02-19","conditions":"Acute Decompensated Heart Failure","enrollment":170},{"nctId":"NCT02329834","phase":"PHASE2, PHASE3","title":"Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously vs. the Same Dose Administered Intravenously in Subjects With Chronic Heart Failure","status":"COMPLETED","sponsor":"scPharmaceuticals, Inc.","startDate":"2015-04","conditions":"Heart Failure","enrollment":23},{"nctId":"NCT04235062","phase":"NA","title":"NATriuretic Response to Expansion and dIUretics in huMans With Heart Failure","status":"COMPLETED","sponsor":"Momentum Research, Inc.","startDate":"2020-04-01","conditions":"Heart Failure","enrollment":229},{"nctId":"NCT04384653","phase":"PHASE1, PHASE2","title":"Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously vs. the Same Dose Administered Intravenously in Subjects With Chronic Heart Failure","status":"COMPLETED","sponsor":"SQ Innovation, Inc.","startDate":"2020-10-17","conditions":"Heart Failure","enrollment":20},{"nctId":"NCT04572867","phase":"NA","title":"Aquapheresis Efficacy in Outpatients With Decompensated Heart Failure","status":"WITHDRAWN","sponsor":"Ramona Gelzer Bell","startDate":"2021-06-08","conditions":"Heart Failure, Congestive Heart Failure, Decompensated Heart Failure","enrollment":""},{"nctId":"NCT03837470","phase":"EARLY_PHASE1","title":"Evaluation of Renal Sodium Excretion After Salt Loading in Heart Failure With Preserved Ejection Fraction","status":"COMPLETED","sponsor":"Adhish Agarwal","startDate":"2019-05-06","conditions":"Heart Failure With Preserved Ejection Fraction","enrollment":14},{"nctId":"NCT04785755","phase":"PHASE2","title":"Effects of Adding Hypertonic Saline Solutions and/or Etilefrine to Standard Diuretics Therapy in Hepatic Ascites","status":"COMPLETED","sponsor":"Hala Abd EL-Tawab Ibrahim Radwan","startDate":"2017-11-30","conditions":"Hepatic Ascites","enrollment":90},{"nctId":"NCT04691687","phase":"PHASE4","title":"OUTpatient Intravenous LASix Trial in Reducing Hospitalization for Acute Decompensated Heart Failure","status":"COMPLETED","sponsor":"New York Presbyterian Brooklyn Methodist Hospital","startDate":"2012-05-01","conditions":"Heart Failure","enrollment":100},{"nctId":"NCT04679571","phase":"NA","title":"Efficacy of Targeted And Response-Guided Albumin Therapy Versus Standard Medical Treatment In Outcomes Of Recurrent Ascites In Patients With Decompensated Cirrhosis.","status":"UNKNOWN","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2020-12-30","conditions":"Decompensated Cirrhosis","enrollment":100},{"nctId":"NCT04628325","phase":"PHASE3","title":"Effects of Furosemide Plus Small HSS in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)","status":"COMPLETED","sponsor":"University of Palermo","startDate":"2017-03-01","conditions":"Heart Failure，Congestive","enrollment":136},{"nctId":"NCT04393493","phase":"PHASE2","title":"The Effect in Renal Function on Patients With Type 1 Cardiorenal Syndrome Treated With Two Strategies of Furosemide.","status":"COMPLETED","sponsor":"Hospital Civil de Guadalajara","startDate":"2017-07-01","conditions":"Cardiorenal Syndrome","enrollment":80},{"nctId":"NCT00624650","phase":"PHASE2","title":"Hemodynamics and Extravascular Lung Water in Acute Lung Injury","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2008-02","conditions":"Acute Lung Injury","enrollment":33},{"nctId":"NCT02802696","phase":"EARLY_PHASE1","title":"Transfusion-Associated Circulatory Overload Best Eliminated With Lasix","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2016-06","conditions":"Transfusion-associated Circulatory Overload","enrollment":80},{"nctId":"NCT01457053","phase":"NA","title":"Assessment of Coronary Flow Reserve in Heart Failure Patients After Ultrafiltration Versus Diuretics","status":"TERMINATED","sponsor":"University of Cincinnati","startDate":"2011-11","conditions":"Acute Decompensated Heart Failure","enrollment":4},{"nctId":"NCT02905760","phase":"PHASE3","title":"Efficacy of Furosemide Versus Vascular Filling in Patients With Acute Myocardial Infarction","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-12","conditions":"Acute Myocardial Infarction With Right Ventricular Extension","enrollment":88},{"nctId":"NCT02821377","phase":"PHASE2","title":"Metabolic Effects of Furosemide +HSS in Refractory Ascites","status":"COMPLETED","sponsor":"University of Palermo","startDate":"2013-12","conditions":"Ascites, Cirrhosis","enrollment":40},{"nctId":"NCT00978354","phase":"PHASE2, PHASE3","title":"Furosemide in Early Acute Kidney Injury","status":"TERMINATED","sponsor":"University of Alberta","startDate":"2009-09","conditions":"Acute Renal Failure","enrollment":72},{"nctId":"NCT01724788","phase":"PHASE1","title":"Pharmacokinetic Profile and Pharmacodynamic Characteristics of a Furosemide High Dosage Formulation in Patients With Chronic Renal Failure Undergoing Peritoneal Dialysis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-11","conditions":"Renal Failure","enrollment":12},{"nctId":"NCT01062776","phase":"PHASE1","title":"Kinetic Method to Detect Dehydration","status":"COMPLETED","sponsor":"Sodertalje Hospital","startDate":"2009-10","conditions":"Dehydration","enrollment":10},{"nctId":"NCT00702728","phase":"PHASE3","title":"Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy (CIN) Prevention","status":"UNKNOWN","sponsor":"Centro Cardiologico Monzino","startDate":"2008-06","conditions":"Contrast Induced Nephropathy","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lasix"],"phase":"marketed","status":"active","brandName":"Furosemide intravenous solution","genericName":"Furosemide intravenous solution","companyName":"Lakeland Regional Health Systems, Inc.","companyId":"lakeland-regional-health-systems-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Furosemide inhibits sodium and chloride reabsorption in the ascending loop of Henle, promoting diuresis and reducing fluid volume. Used for Edema associated with congestive heart failure, Edema associated with hepatic cirrhosis, Edema associated with renal disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}